Biosyent Inc. Market Cap ($133.46 Million)
Market Cap & Net Worth: Biosyent Inc. (RX)
Biosyent Inc. market cap. Biosyent Inc. (V:RX) has a market capitalization of $133.46 Million (CA$184.49 Million) as of November 1, 2026. Listed on the V stock exchange, this Canada-based company holds position #17928 globally and #576 in its home market, demonstrating a 0.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biosyent Inc.'s stock price CA$17.09 by its total outstanding shares 11262282 (11.26 Million). Also see cash efficiency ratio of Biosyent Inc. for how efficiently the company converts equity into cash flow.
Biosyent Inc. Market Cap History (2015–2026)
Biosyent Inc. market cap history from 2015 to 2026. Data shows growth from $54.55 Million to $139.23 Million (8.86% CAGR). Check RX share price today for real-time trading data and today's change.
Biosyent Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biosyent Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Biosyent Inc. growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.56x
Biosyent Inc.'s market cap is 2.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.33x
Biosyent Inc.'s market cap is 12.33 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $54.55 Million | $15.39 Million | $3.76 Million | 3.54x | 14.49x |
| 2016 | $62.34 Million | $17.92 Million | $4.31 Million | 3.48x | 14.47x |
| 2017 | $74.81 Million | $20.76 Million | $5.21 Million | 3.60x | 14.37x |
| 2018 | $62.81 Million | $21.53 Million | $5.71 Million | 2.92x | 11.01x |
| 2019 | $47.53 Million | $21.42 Million | $4.37 Million | 2.22x | 10.88x |
| 2020 | $61.64 Million | $22.33 Million | $3.80 Million | 2.76x | 16.24x |
| 2021 | $64.37 Million | $28.62 Million | $6.28 Million | 2.25x | 10.25x |
| 2022 | $54.85 Million | $27.93 Million | $5.46 Million | 1.96x | 10.05x |
| 2023 | $73.75 Million | $31.59 Million | $6.46 Million | 2.33x | 11.42x |
| 2024 | $89.62 Million | $35.03 Million | $7.27 Million | 2.56x | 12.33x |
Competitor Companies of RX by Market Capitalization
Companies near Biosyent Inc. in the global market cap rankings as of November 1, 2026. Also see Biosyent Inc. asset portfolio for a full breakdown of the balance sheet.
Key companies related to Biosyent Inc. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Biosyent Inc. (2015–2026)
Market capitalization of Biosyent Inc. from 2015 to today. Between 2015 and today, Biosyent Inc.'s market cap moved from $54.55 Million to $ 139.23 Million, with a yearly change of 8.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$139.23 Million | +34.25% |
| 2025 | CA$103.71 Million | +15.73% |
| 2024 | CA$89.62 Million | +21.51% |
| 2023 | CA$73.75 Million | +34.46% |
| 2022 | CA$54.85 Million | -14.78% |
| 2021 | CA$64.37 Million | +4.42% |
| 2020 | CA$61.64 Million | +29.67% |
| 2019 | CA$47.53 Million | -24.32% |
| 2018 | CA$62.81 Million | -16.04% |
| 2017 | CA$74.81 Million | +20.00% |
| 2016 | CA$62.34 Million | +14.29% |
| 2015 | CA$54.55 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Biosyent Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $133.46 Million USD |
| MoneyControl | $133.46 Million USD |
| MarketWatch | $133.46 Million USD |
| marketcap.company | $133.46 Million USD |
| Reuters | $133.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form produc… Read more